Skip to content
BoardCited

Drug product selection: generic substitution, Orange Book, biosimilars and interchangeability

3 free Uniform MPJE practice questions on this topic, with the answer, a reason for every option and the source. The full bank has 30 questions here.

Question 1Single answer

FDA's publication "Approved Drug Products With Therapeutic Equivalence Evaluations" is commonly known as the:

  1. AOrange Book
  2. BPurple Book
  3. CNational Formulary
Show answer and sources

Answer: A. Orange Book

Listed drugs appear in FDA's "Approved Drug Products With Therapeutic Equivalence Evaluations," the Orange Book (21 CFR 314.3(b)).

  • A. Correct. That is the formal title of the Orange Book.
  • B. Wrong. The Purple Book is FDA's database of licensed biological products.
  • C. Wrong. The National Formulary is a USP compendium of standards, not FDA's list of approved drugs with equivalence ratings.
  1. [1] 21 CFR Part 314 — Applications for FDA approval (Orange Book TE) . § 314.3(b)
Question 2Single answer

A pharmacist checks the Orange Book and finds that a generic tablet is coded AB in relation to the brand-name tablet on the prescription. This code means FDA:

  1. Ahas not yet determined whether it is therapeutically equivalent
  2. Bconsiders it therapeutically equivalent, with bioequivalence shown
  3. Cconsiders it equivalent only if it has the same inactive ingredients
Show answer and sources

Answer: B. considers it therapeutically equivalent, with bioequivalence shown

A first letter A means FDA considers the product therapeutically equivalent to other pharmaceutically equivalent products, and AB products met the necessary bioequivalence requirements (Orange Book Preface, section 1.7).

  • A. Wrong. That describes codes such as BX or B*, not AB.
  • B. Correct. A codes mean therapeutic equivalence; AB products met the bioequivalence requirements.
  • C. Wrong. Pharmaceutical equivalents need not have the same inactive ingredients.
  1. [1] Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), March 20, 2020 (BPCIA transition) edition - Preface and Section 1 (pp. i-xxiv); text checked against the current 46th-edition online Preface (fda.gov, content current as of 01/15/2026) . Orange Book Preface § 1.7 (AB) heading; Orange Book Preface § 1.7
Question 3Single answer

A patient notices that her new generic tablet contains a different dye and filler than the brand. The generic has the same active ingredient, salt, strength, dosage form and route as the brand. Which statement is correct?

  1. AIt cannot be a pharmaceutical equivalent with different excipients
  2. BIt can still be a pharmaceutical equivalent of the brand
  3. CIt is a pharmaceutical alternative due to excipients
Show answer and sources

Answer: B. It can still be a pharmaceutical equivalent of the brand

Pharmaceutical equivalents have identical amounts of the identical active ingredient in identical dosage forms and routes, but do not necessarily contain the same inactive ingredients (21 CFR 314.3(b)).

  • A. Wrong. 21 CFR 314.3(b) states inactive ingredients need not be the same.
  • B. Correct. Pharmaceutical equivalents need not contain the same inactive ingredients.
  • C. Wrong. Pharmaceutical alternatives differ in salt, amount or dosage form, not excipients.
  1. [1] 21 CFR Part 314 — Applications for FDA approval (Orange Book TE) . § 314.3(b)

Practise all 30 questions on this topic

Tutor mode, timed blocks and progress tracking.

Start free